Get started
Mirum Pharmaceuticals, Inc.Mirum Pharmaceuticals, Inc.Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options Bonds

MIRM trade ideas

MIRM expecting something bigThis stock was a pendulum pick (as in from dowsing) from around August. I posted an idea at the time, and it's gone up, but been consolidating. Last week or so, I decided to let my dowsing choose a stock from the fi viz screener from ALL exchanges. There were over 9500 stock tickers & you know which one I landed on??? Yeah, MIRM again. This is virtually impossible, & really got me fired up. I decided to check the option and that day (early last week I think) there were 1900 calls bought for next months $45 strike. MIRM trades NO options, so this is extra interesting. And I happened to look on the day they were all purchase at once, or at least on the same day. I will still expect the original target, though I do need to verify this still. I just can't help think something is brewing here.
NASDAQ:MIRMLong
by JenRz
MIRM buy the dip pendulum pickMy psychic friend (whom I've mentioned in other ideas) suggested I look to a pharma stock, so I put in all of healthcare of optionable stocks on a screener & this is the stock my dowsing chose. The message is that it's going to have some kinda dump. Maybe a downgrade or something that sends it possibly as low as $33. The zone of $35-36 came in as well. I suppose it's possible the $33 could come in the globex session cuz I've had that before. The main idea, however, is to buy this dip as it should reverse back up somewhat quickly. The date of the potential low is the 29th. That is the date I get to take some action on it, so we'll see. Over the next couple months I believe this could continue to rise and the target I get is up at $57. Seems ambitious, but it does happen, so I'm just reporting what I get & you can be the judge. I ask for when this might hit & get Oct. 23rd. I don't have tons of faith this is how it will shake out, but those dates are relevant sometimes. So, watch and see!
NASDAQ:MIRMLong
by JenRz
Mirum Pharmaceuticals (MIRM) AnalysisAdvancements in Rare Disease Therapies: Mirum Pharmaceuticals NASDAQ:MIRM is advancing in the biopharma sector with a focus on therapies for rare diseases. Recently, Mirum submitted a New Drug Application (NDA) for chenodiol tablets to treat cerebrotendinous xanthomatosis (CTX), following positive phase 3 RESTORE trial results. FDA approval could be a breakthrough for early diagnosis and treatment of this rare disease. Positive Market Response: CEO Chris Peetz highlighted the potential impact of chenodiol in alleviating CTX symptoms. Wall Street has responded positively, with Citi raising their price target for Mirum to $64 from $38 and maintaining a Buy rating, reflecting confidence in Mirum's pipeline and recent updates on volixibat and FDA-approved Livmarli. Investment Outlook: Bullish Outlook: We are bullish on MIRM above the $29.00-$30.00 range. Upside Potential: With an upside target set at $48.00-$49.00, investors should consider Mirum's promising pipeline and recent regulatory advancements as key drivers for potential stock appreciation. 📊💊 Monitor Mirum Pharmaceuticals for promising investment opportunities! #MIRM #BiopharmaGrowth 📈🔍
NASDAQ:MIRMLong
by Richtv_official
$MIRM september accumulation 👁‍🗨*This is not financial advice, so trade at your own risks* *My team digs deep and finds stocks that are expected to perform well based off multiple confluences* *Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management* Mirum Pharmaceuticals announced a shelf offering of $10 million today. This created an excellent buying opportunity which we used as our first entry. My team will be using the rest of September to build our position. We are expecting a bullish run before the end of the year, but if one happens sooner, we will of course act in our favor and do what we think is best. Entry: $22.80 Take Profit: Somewhere above $32 If you want to see more, please like and follow us @SimplyShowMeTheMoney
NASDAQ:MIRMLong
by SimplyShowMeTheMoney
$MIRM bear proof 👁‍🗨 *This is not financial advice, so trade at your own risks* *My team digs deep and finds stocks that are expected to perform well based off multiple confluences* *Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management My team entered Mirum Pharmaceuticals $MIRM today at $25 per share. Our take profit is $30. We also have a stop less set at $24 OUR ENTRY: $25 FIRST TAKE PROFIT: $30 STOP LOSS: $24 If you want to see more, please like and follow us @SimplyShowMeTheMoney
NASDAQ:MIRMLong
by SimplyShowMeTheMoney
4
$MIRM sniper edition #2*This is not financial advice, so trade at your own risks* *My team digs deep and finds stocks that are expected to perform well based off multiple confluences* *Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management* Recap: My team entered $MIRM on October 29, 2021 at $15.70 per share. Our first take profit is at $21. My team averaged down on our position today at $13.57 per share bringing our share average to $14.63 per share. Our First Entry: $15.70 Our 2nd Entry: $13.57 First Take Profit: $21 2nd Take Profit: $26 If you want to see more, please like and follow us @SimplyShowMeTheMoney
NASDAQ:MIRMLong
by SimplyShowMeTheMoney
$MIRM november update*This is not financial advice, so trade at your own risks* *My team digs deep and finds stocks that are expected to perform well based off multiple confluences* *Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management* Recap: My team entered $MIRM on 10/29/21 at $15.70 per share. Our first take profit is at $26. Mirum Pharmaceuticals $MIRM released their 3rd quarter earnings today after market close. In this report they announced a loss of -$1.55 per share on revenue of $5.0 million. This earnings beat is staggering, especially when acknowledging the fact that the revenue consensus was only $0.8 million. $MIRM is still an under the radar company currently, but a revenue beat of 502.4% will definitely turn some heads. In addition, post-earnings five insiders accumulated a vast amount of shares. These insiders know what's coming, and lucky for us we do too. Our first take profit is honestly a huge underestimate of this companies potential, and in the future we may have to make some major adjustments. This is a buy and throw away the key type of investment. My teams holding! Will you? OUR ENTRY: $15.70 FIRST TAKE PROFIT: $26 If you want to see more, please like and follow us @SimplyShowMeTheMoney
NASDAQ:MIRMLong
by SimplyShowMeTheMoney
4
$MIRM empire strikes back*This is not financial advice, so trade at your own risks* *My team digs deep and finds stocks that are expected to perform well based off multiple confluences* *Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management* If you take the chance to review our previous works, you may have noticed a simple trend...we are getting to the money every time! However despite our many triumphs there are plays that we prefer not to discuss amongst ourselves. From that tiny list $MIRM is definitely at the top. In the past my team doubled down on a position but we were wiped out after our stop-loss took us out of the trade. My team entered $MIRM on 10/29/21 at $15.70 per share. Our first take profit is at $26. Earnings are expected to be released on 11/3/21 Ego is a bitch. Lets get it. OUR ENTRY: $15.70 FIRST TAKE PROFIT: $26 If you want to see more, please like and follow us @SimplyShowMeTheMoney
NASDAQ:MIRMLong
by SimplyShowMeTheMoney
$MIRM doubling down*This is not financial advice, so trade at your own risks* *My team digs deep and finds stocks that are expected to perform well based off multiple confluences* *Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management* Recap: My team entered $MIRM on 5/28/21 at $16.30 per share. Today we're taking the dip opportunity and doubling down at $15.60 per share. FIRST ENTRY: $16.30 2ND ENTRY: $15.60 TAKE PROFIT 1: $20 TAKE PROFIT 2: $30 STOP LOSS: $14.90 If you want to see more, please like and follow us @SimplyShowMeTheMoney
NASDAQ:MIRMLong
by SimplyShowMeTheMoney
$MIRM June Update*This is not financial advice, so trade at your own risks* *My team digs deep and finds stocks that are expected to perform well based off multiple confluences* *Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management* Mirum Pharmaceuticals: My team has been reviewing Mirum Pharmaceuticals for close to two months, and despite its poor performance in the past month it remains one of top picks for the month of June. $MIRM is to release data collected on maralixibat on 6/5/21. Tomorrow morning we are averaging up on our positions at $17.00. Our original entry was at $16.30. Short term take profit @$20.00 Long Term take profit $26.00 If you want to see more, please like and follow us @SimplyShowMeTheMoney
NASDAQ:MIRMLong
by SimplyShowMeTheMoney
Mirum Insane Catalyst Play*This is not financial advice, so trade at your own risks* *My team digs deep and finds stocks that are expected to perform well based off multiple confluences* *Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management* Mirum Pharmaceuticals: My team has been reviewing Mirum Pharmaceuticals for close to two months, and despite its poor performance in the past month it remains one of top picks for the month of June. Mirm is to present data for their assets which target rare liver diseases on June 3rd 2021. Its recent price rejection at $15.85 increases our confidence in this play. There have been jumps from this zone up to $20-26, so we expect a similar pattern to repeat. Next week's data results simply have to be adequate enough to regain investor attention. My team is especially confident in the risk-to-reward ratio of this trade. We entered today @$16.30. Short term take profit @$20.00 Long Term take profit @$30.00 Stop Loss @$14.90 If you want to see more, please like and follow us @SimplyShowMeTheMoney
NASDAQ:MIRMLong
by SimplyShowMeTheMoney